Cargando…

Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation

OBJECTIVES: Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayoglu, Burcu, Donato, Michele, Furst, Daniel E, Crofford, Leslie J, Goldmuntz, Ellen, Keyes-Elstein, Lynette, James, Judith, Macwana, Susan, Mayes, Maureen D, McSweeney, Peter, Nash, Richard A, Sullivan, Keith M, Welch, Beverly, Pinckney, Ashley, Mao, Rong, Chung, Lorinda, Khatri, Purvesh, Utz, Paul J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Systemic Sclerosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10176357/ https://www.ncbi.nlm.nih.gov/pubmed/36653124 http://dx.doi.org/10.1136/ard-2021-221926

Ejemplares similares

Myeloablative autologous haematopoietic stem cell transplantation resets the B cell repertoire to a more naïve state in patients with systemic sclerosis
por: Adamska, Julia Z, et al.
Publicado: (2023)

Haematopoietic stem cell transplantation in systemic sclerosis
por: Walker, Ulrich A, et al.
Publicado: (2018)

Reply to Andréasson et al.: Multiple Manifestations of Systemic Sclerosis Affect Walk Distance
por: Zamanian, Roham T., et al.
Publicado: (2021)

Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis
por: Spiera, Robert, et al.
Publicado: (2020)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Autologous haematopoietic stem cell transplantation versus low‐dose immunosuppression in secondary–progressive multiple sclerosis
por: Mariottini, Alice, et al.
Publicado: (2022)

Long‐Term Outcomes in Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension in the Modern Treatment Era: Meta‐Analyses of Randomized, Controlled Trials and Observational Registries
por: Khanna, Dinesh, et al.
Publicado: (2021)

Adipose‐Derived Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
por: Khanna, Dinesh, et al.
Publicado: (2022)

Caphosol for prevention of oral mucositis in pediatric myeloablative haematopoietic cell transplantation
por: Treister, Nathaniel, et al.
Publicado: (2017)

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial
por: Maher, Toby M., et al.
Publicado: (2021)

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON
por: Allanore, Yannick, et al.
Publicado: (2022)

Fibrinolysis-independent role of plasmin and its activators in the haematopoietic recovery after myeloablation
por: Tjwa, Marc, et al.
Publicado: (2009)

Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
por: Cohen, Jeffrey A, et al.
Publicado: (2016)

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score
por: Kuwana, Masataka, et al.
Publicado: (2022)

Comprehensive analysis of the major histocompatibility complex in systemic sclerosis identifies differential HLA associations by clinical and serological subtypes
por: Acosta-Herrera, Marialbert, et al.
Publicado: (2021)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Memory in multiple sclerosis is linked to glutamate concentration in grey matter regions
por: Muhlert, Nils, et al.
Publicado: (2014)

Tobacco smoking and excess mortality in multiple sclerosis: a cohort study
por: Manouchehrinia, Ali, et al.
Publicado: (2014)

Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial
por: Olsson, Tomas, et al.
Publicado: (2014)

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT
por: Edan, G, et al.
Publicado: (2014)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

Changes to anti-JCV antibody levels in a Swedish national MS cohort
por: Warnke, Clemens, et al.
Publicado: (2013)

Incidence and prevalence of multiple sclerosis in the UK 1990–2010: a descriptive study in the General Practice Research Database
por: Mackenzie, I S, et al.
Publicado: (2014)

Re-evaluating the treatment of acute optic neuritis
por: Bennett, Jeffrey L, et al.
Publicado: (2015)

The grey matter correlates of impaired decision-making in multiple sclerosis
por: Muhlert, Nils, et al.
Publicado: (2015)

MRI in Leber's hereditary optic neuropathy: the relationship to multiple sclerosis
por: Matthews, Lucy, et al.
Publicado: (2015)

Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis
por: De Stefano, Nicola, et al.
Publicado: (2016)

A 60-year follow-up of the incidence and prevalence of multiple sclerosis in Hordaland County, Western Norway
por: Grytten, N, et al.
Publicado: (2016)

Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
por: Haider, Lukas, et al.
Publicado: (2014)

Imaging outcomes for trials of remyelination in multiple sclerosis
por: Mallik, Shahrukh, et al.
Publicado: (2014)

HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study
por: Gold, Julian, et al.
Publicado: (2015)

DIR-visible grey matter lesions and atrophy in multiple sclerosis: partners in crime?
por: van de Pavert, Steven H P, et al.
Publicado: (2016)

High consumption of coffee is associated with decreased multiple sclerosis risk; results from two independent studies
por: Hedström, A K, et al.
Publicado: (2016)

Therapeutic and diagnostic outcomes of a standardised, comprehensive care pathway for patients with systemic sclerosis
por: Meijs, Jessica, et al.
Publicado: (2016)

Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15
por: Kappos, Ludwig, et al.
Publicado: (2015)

TRAIL and TRAIL receptors splice variants during long-term interferon β treatment of patients with multiple sclerosis: evaluation as biomarkers for therapeutic response
por: López-Gómez, Carlos, et al.
Publicado: (2016)

Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
por: McGuigan, C, et al.
Publicado: (2016)

Failed Degradation of JunB Contributes to Overproduction of Type I Collagen and Development of Dermal Fibrosis in Patients With Systemic Sclerosis
por: Ponticos, Markella, et al.
Publicado: (2015)

A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis
por: Thomas, Sarah, et al.
Publicado: (2013)

Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients
por: Dahlhaus, Stefanie, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_v5aoc61bo7k9fg580fmubkv0br